Neuromuscular Diseases
Read Time: 2 mins

The Long-term Treatment of Multifocal Motor Neuropathy with Intravenous Immunoglobulin

Copy Link
Published Online: May 15th 2012 European Neurological Review, 2012;7(2):128-133 DOI:
Authors: Leonard H van den Berg
Quick Links:
Article Information

Multifocal motor neuropathy (MMN) is a rare, purely motor neuropathy. It is a progressive disorder, most patients eventually developing severe fatigue and weakness in the arm muscles that severely impair daily functioning and quality of life. Unlike other motor neuropathies such as motor neurone disease, MMN is treatable with regular infusions of intravenous immunoglobulin (IVIg). Four double-blind, randomised, placebo-controlled studies have shown that in the short term, IVIg significantly improves muscle strength and disability in more than 70 % of patients. The 11 observational studies reviewed in this article confirm that long-term maintenance treatment with IVIg maintains clinical improvement compared to pre-treatment baseline in most patients. Infusions are generally well tolerated, but regular monitoring and re-evaluation of the IVIg maintenance regimen is essential, as most patients need progressive increases in dosage or reduced intervals between infusions to maintain their response to treatment. In the absence of accepted predictive markers, maintenance IVIg should be individualised, based on each patient’s initial response, disability and the interval between the first infusion and decline in muscle strength.


Multifocal motor neuropathy, intravenous immunoglobulin, maintenance, treatment


Multifocal motor neuropathy (MMN) is a rare, purely motor neuropathy with a prevalence of approximately 0.6 per 100,000 and a median age of onset of 40 years.1 Men are more likely than women to be affected, in a ratio of 2.7:1 and are usually diagnosed at an earlier age.1 Patients with MMN typically present with asymmetrical, predominantly distal limb weakness that follows individual nerves. There is no apparent sensory loss and weakness usually starts in the forearm or hand muscles, though the first symptoms may occur in the distal leg and upper arm. Respiratory and bulbar muscles are unaffected and patients have a normal life expectancy. However, since MMN is a progressive disorder, most patients eventually develop severe fatigue and weakness in the arm muscles, resulting in disability that can seriously impair daily functioning and quality of life.

Unlike other motor neuropathies such as motor neurone disease (MND), MMN is treatable with intravenous immunoglobulin (IVIg).2 Most patients require regular infusions in order to maintain clinical response and the aim of this review is to consider the effectiveness and safety of long-term or maintenance treatment of MMN with IVIg.

The terms ‘multifocal motor neuropathy’, ‘treatment’, ‘long term’, ‘maintenance’ and ‘IVIg’ were used to conduct a PubMed search of articles published in English language journals between 1 January 1980 and 31 December 2011 (see Table 1). Papers were excluded ifthey were single case reports, or were superseded by subsequent publications following up the same group of patients.

The manual search of the results of the PubMed literature searchidentified a total of 14 studies concerning the long-term or maintenance treatment of MMN with IVIg. Three papers were excluded:

  • a case report in one patient;3
  • a publication concerning six patients included in a subsequent, larger study;4,5
  • and a study of dose titration in patients on maintenance IVIg.6

The remaining 11 studies listed in Table 2 were included in the analysis.1,5,7–15 All were retrospective, observational studies, except for one cross-sectional, descriptive study.

To view the full article in PDF or eBook formats, please click on the icons above.

Article Information:

Leonard H van den Berg has received a travel grant and honoraria from Baxter International Inc.


Leonard H van den Berg, Department of Neurology G03.228, PO Box 85500, 3508 GA Utrecht, The Netherlands. E:


The publication of this article was funded by Baxter Innovations GmbH. The views and opinions expressed are those of the author and not necessarily those of Baxter Innovations GmbH.




  1. Cats EA, van der Pol WL, Piepers S, et al., Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy, Neurology, 2010;75:818–25.
  2. Van Schaik IN, van den Berg LH, de Haan R, Vermeulen M, Intravenous immunoglobulin for multifocal motor neuropathy (Review), Cochrane Database Syst Rev, 2005;2:CD004429.
  3. Van den Berg LH, Franssen H, Wokke JH, Improvement of multifocal motor neuropathy during long-term weekly treatment with human immunoglobulin, Neurology, 1995;45(5):987–8.
  4. Van den Berg LH, Franssen H, Wokke JH, The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy, Brain, 1998;121(Pt. 3):421–8.
  5. Van den Berg-Vos RM, Franssen H, Wokke JH, Van den Berg LH, Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment, Brain, 2002;125:1875–86.
  6. Baumann A, Hess CW, Sturzenegger M, IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up, J Neurol, 2009;256(4):608–14.
  7. Azulay JP, Rihet P, Pouget J, et al., Long term follow up of multifocal motor neuropathy with conduction block under treatment, J Neurol Neurosurg Psychiatry, 1997;62:391–4.
  8. Delmont E, Azulay JP, Giorgi R, et al., Multifocal motor neuropathy with and without conduction block: a single entity?, Neurology, 2006;67:592–6.
  9. Jaspert A, Claus D, Grehl H, Neundörfer B, Multifocal motor neuropathy: clinical and electrophysiological findings, J Neurol, 1996;243:684–92.
  10. Léger JM, Viala K, Cancalon F, et al., Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients, J Neurol Neurosurg Psychiatry, 2008;79:93–6.
  11. Lucas M, Hugh-Jones K, Welby A, et al., Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance and self-infusion at home, J Clin Immunol, 2010;30(Suppl. 1):S84–9.
  12. Meucci N, Cappellari A, Barbieri S, et al., Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy, J Neurol Neurosurg Psychiatry, 1997;63:765–9.
  13. Slee M, Selvan A, Donaghy M, Multifocal motor neuropathy: the diagnostic spectrum and response to treatment, Neurology, 2007;69:1680–7.
  14. Terenghi F, Cappellari A, Bersano A, et al., How long is IVIg effective in multifocal motor neuropathy?, Neurology, 2004;62:666–8.
  15. Vucic S, Black KR, Chong PS, Cros D, Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg, Neurology, 2004;63:1264–9.
  16. Joint Task Force of the EFNS and PNS, European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision, Eur J Neurol, 2010;17:356–63.
  17. Van den Berg LH, Lokhorst H, Wokke JH, Pulsed high-dose dexamethasone is not effective in patients with multifocal motor neuropathy, Neurology, 1997;48:1135.
  18. Carpo M, Cappellari A, Mora G, et al., Deterioration of multifocal motor neuropathy after plasma exchange, Neurology, 1998;50:1480–2.
  19. Léger JM, Lievens I, Multifocal motor neuropathy: and then, 20 years later…IVIg therapy, Schweizer Archiv für Neurologie und Psychiatrie, 2007;158:81–5.
  20. Umapathi T, Hughes RAC, Nobile-Orazio E, Léger JM, Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy, Cochrane Database Syst Rev, 2009;1:CD003217.
  21. Piepers S, Van den Berg-Vos R, Van der Pol WL, et al., Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial, Brain, 2007;130:2004–10.
  22. Azulay JP, Blin O, Pouget J, et al., Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a doubleblind, placebo-controlled study, Neurology, 1994;44:429–32.
  23. Federico P, Zochodne DW, Hahn AF, et al., Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study, Neurology, 2000;55:1256–62.
  24. Léger JM, Chassande B, Musset L, et al., Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study, Brain, 2001;124:145–53.
  25. Van den Berg LH, Kerkhoff H, Oey PL, et al., Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study, J Neurol Neurosurg Psychiatry, 1995;59:248–52.
  26. Van Asseldonk JT, Van den Berg LH, Kalmijn S, et al., Axon loss is an important determinant of weakness in multifocal motor neuropathy, J Neurol Neurosurg Psychiatry, 2006;77:743–7.
  27. Van der Pol W-L, Cats EA, van den Berg LH, Intravenous immunoglobulin treatment in multifocal motor neuropathy, J Clin Immunol, 2010;30(Suppl. 1):S79–83.
  28. Vlam L, van der Pol L, Cats EA, et al., Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies, Nat Rev Neurol, 2011;8:48–58.
  29. Cats EA, van der Pol WL, Bertens AS, van den Berg LH, Home-based IVIg treatment is convenient and time-saving in patients with multifocal motor neuropathy, J Peripher Nerv Syst, 2011;16:147–9.
  30. Eftimov F, Vermeulen M, de Haan RJ, et al., Subcutaneous immunoglobulin therapy for multifocal motor neuropathy, J Peripher Nerv Syst, 2009;14:93–100.
  31. Harbo T, Andersen H, Hess A, et al., Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial, Eur J Neurol, 2009;16:631–8.
  32. Misbah SA, Baumann A, Fazio R, et al., A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open label proof-of-concept study, J Peripher Nerv Syst, 2011;16:92–7.

Further Resources

Share this Article
Related Content In Neuromuscular Diseases
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72